Mrs. Mary Kay Rich, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3071 Highway 15, Shelbyville, MO 63469 Phone: 573-633-2401 Fax: 573-633-2138 |
News Archive
Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.
A new drug launched today could help in the fight against what experts and campaigners are calling a 'major patient safety issue' - the prevention of hospital-acquired DVT (deep vein thrombosis).
According to Queensland Premier Anna Bligh, new developments are on the horizon only if her Government continues with the sell off of $15 billion of public assets. She revealed this in her annual State of the State address at the mid point of her term in Government yesterday while reviewing the past 18 months and forecasting the next stage of the state's development.
› Verified 6 days ago